XTRA:DMPPharmaceuticals
Assessing Dermapharm Holding (XTRA:DMP) Valuation After Strong Q1 Results And Reaffirmed Outlook
Dermapharm Holding (XTRA:DMP) just reported first quarter 2026 results, with sales of €309.1 million, net income of €45.2 million and earnings per share of €0.84 from continuing operations.
See our latest analysis for Dermapharm Holding.
The strong Q1 release, including higher revenue, net income and reaffirmed guidance, has coincided with a clear upswing in momentum, with a 40.38% 90 day share price return and a 55.95% 1 year total shareholder return from Dermapharm Holding.
If this earnings...